Tuesday, 21 June 2011
08:30-10:00 | Plenary session: Primary prevention and early detection
of melanoma: hot topics today
Chairs: Luc Thomas (France), Hubert Pehamberger (Austria), Michael Binder (Austria)
- EPIDERM: Results of an EU-project against skin cancer
Eggert Stockfleth (Germany) - Sunbed and melanoma risk: myth or reality?
Isabel Longo (Spain) - Euromelanoma: results of a pan European skin cancer prevention campaign
Véronique Del Marmol (Belgium) - Photo protection, vitamin D: where we are today?
Marjam Barysch (Switzerland) - Follow up strategies for Nevi: is it still of interest?
Jean-Jacques Grob (France) - New concepts in nevogenesis
Iris Zalaudek (Austria)
- Take home messages Ketty Peris (Italy)
10:00-10:30 | Coffee break - Sponsored by Bristol-Myers Squibb
10:30-11:00 | Guest Lecture
Chairs: Georg Weinlich (Austria), Isabel Longo (Spain)
- • Innate Immunity and melanoma: current status and perspective Georg Stingl (Austria)
11:00-12:30 | Plenary session: Melanoma management
Sponsored by MSD
Chairs: Josep Malvehy (Spain), Caroline Robert (France), Axel Hauschild (Germany)
- Next staging classification?
Jeffrey Gershenwald (United States) - New standards of pathology reporting
Alain Spatz (Canada) - Biomarkers of interferon responsiveness useful in routine
Helen Gogas (Greece) - Prognostic factors for sentinel lymph nodes and adjuvant treatment
Vernon Sondak (United States) - An evidence based approach to excision margins of melanoma
Philippe Saiag (France)
- Take home messages Dirk Schadendorf (Germany)
12:30-14:00 | Lunch Sponsored by Bristol-Myers Squibb - Posters session
12:30-14:00 | Satellite symposium Bristol-Myers Squibb:
New frontiers in melanoma: changing the treatment paradigm
in advanced disease
Chairs: Caroline Robert (France), Reinhard Dummer (Switzerland)
- Welcome and introductions
- Recent advances in the treatment of advanced melanoma
Caroline Robert (France) - Integrating new treatments into patient care: what are the practical considerations?
Reinhard Dummer (Switzerland)
14:00-15:30 | Free oral commnunications 2: Melanoma - part 2
Chairs: Alain Spatz (Canada), Peter Arenberger (Czech Republic), Marie-Françoise Avril (France)
CO10 | Importance of duration of high-dose interferon-alfa in the adjuvant therapy of melanoma
Agarwala SS (USA)
CO11 | 131I targeted radionuclide therapy by melanin linked molecules for melanoma treatment
Bonnet M, Besse S, Jacquemot N, Communal Y, Papon J, Mishellany F, Cayre A, Penault-Llorca F, Miot-Noirault E, Doly M, Chezal JM, Cluzel J, Moins N, Degoul F (France)
CO12 | Chemoablation of metastatic melanoma with intralesional PV-10
Agarwala SS, Thompson JF, Smithers BM, Ross MI, Coventry BJ, Minor DR, Scoggins CR, Wachter EA (Australia, USA)
CO13 | Sinonasal mucosal melanomas. About the impact of initial localization and therapeutic modalities on survival: a series of 35 cases
Perret-Court A, Mancini J, Richard MA, Michel J, Monestier S, Giovanni A, Grob JJ (France)
CO14 | A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC)
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang ALS, Low JA, Mueller AB, Yauch RL, Reddy JC, Hauschild A (USA)
CO15 | The DEPIMELA study: The melanoma/naevus ratio according to dermoscopy method and melanoma risk factors
Tromme I, Sacré L, Hammouch F, Vereecken P, Marot L, Baurain JF, Thomas L, Speybroeck N (Belgium, France)
CO16 | The Mitogen Activated Protein Kinase pathway regulates the expression of p18INK4c and p21Waf1/Cip1 cyclin-dependent kinase inhibitors through the activating protein-1 transcription factor
Jalili A, Wagner C, Mertz KD, Pashenkov M, Stingl G, Ramaswamy S, Wagner SN (Austria, Russia, USA)
CO17 | Can we further increase benefit for Interferon therapy by selecting patients on certain risk factors
Mohr P (Germany)
CO18 | The analytic performance of the cobas® 4800 BRAF V600 Mutation Test in the detection of V600E mutations in malignant melanoma: assay reproducibility and effects of melanin
Kovach B, Langland R, Schilling R, Halait H, Anderson S, Bloom K, Vallera DU, Rueschoff J, Lawrence HJ (USA, Germany)
15:30-16:00 | Coffee break Sponsored by Bristol-Myers Squibb
16:00-17:00 | Plenary session: Ongoing clinical trials - Sponsored by GlaxoSmithKline
Chairs: Jerry Marsden (United Kingdom), Peter Hersey (Australia), Brigitte Dréno (France)
- Melanoma
Axel Hauschild (Germany) - Lymphoma
Robert Knobler (Austria) - Non melanoma skin cancer
Céleste Lebbé (France)
- Take home messages John Kirkwood (United States)
17:00-18:30 | Satellite symposium Roche:
Advances in Skin Cancer - Finding a Tailored Solution for Patients
Chair : Brigitte Dréno (France)
- Welcome and Introduction – Signaling Pathways in Melanoma and Non-melanoma Skin Cancer
Brigitte Dréno (France) - Re-defining the Treatment of Metastatic Melanoma: From Chemotherapy to Individualized
Targeted Therapies
Mark Middleton (United Kingdom) - Inhibition of RAF Pathway: Targeted Approach for Metastatic Melanoma
Axel Hauschild (Germany) - Mechanisms of Hedgehog Pathway Activation in Basal Cell Carcinoma
Dirk Schadendorf (Germany) - Targeting Hedgehog as a Therapeutic Approach to Basal Cell Carcinoma
Aleksandar Sekulic (USA) - Q&A and Closing Remarks
Brigitte Dréno (France)